Lataa...
Glembatumumab vedotin for patients with metastatic, gpNMB overexpressing, triple-negative breast cancer (“METRIC”): a randomized multicenter study
The METRIC study (NCT#0199733) explored a novel antibody–drug conjugate, glembatumumab vedotin (GV), targeting gpNMB that is overexpressed in ~40% of patients with triple-negative breast cancer (TNBC) and associated with poor prognosis. The study was a randomized, open-label, phase 2b study that eva...
Tallennettuna:
| Julkaisussa: | NPJ Breast Cancer |
|---|---|
| Päätekijät: | , , , , , , , , , , , , , , , , , |
| Aineistotyyppi: | Artigo |
| Kieli: | Inglês |
| Julkaistu: |
Nature Publishing Group UK
2021
|
| Aiheet: | |
| Linkit: | https://ncbi.nlm.nih.gov/pmc/articles/PMC8137923/ https://ncbi.nlm.nih.gov/pubmed/34016993 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1038/s41523-021-00244-6 |
| Tagit: |
Lisää tagi
Ei tageja, Lisää ensimmäinen tagi!
|